Published in J Hypertens on December 01, 2004
VALUE and supremacy of blood pressure control for cardiovascular protection. J Hypertens (2004) 2.05
VALUE: to the heart of the matter. J Hypertens (2004) 1.40
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Sodium intake and mortality in the NHANES II follow-up study. Am J Med (2006) 3.24
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III). J Gen Intern Med (2008) 1.79
A call for higher standards of evidence for dietary guidelines. Am J Prev Med (2008) 1.69
Effect of physician volume on the relationship between hospital volume and mortality during primary angioplasty. J Am Coll Cardiol (2009) 1.67
Acute myocardial infarction hospitalization in the United States, 1979 to 2005. Am J Med (2010) 1.63
Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am J Hypertens (2013) 1.57
Hypertension control at physicians' offices in the United States. Am J Hypertens (2008) 1.56
Renal dysfunction and ischemic heart disease mortality in a hypertensive population. J Hypertens (2005) 1.55
Is high pulse pressure a marker of preclinical cardiovascular disease? Hypertension (2005) 1.53
Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens (2011) 1.27
Blood-pressure-related disease is a global health priority. Lancet (2008) 1.22
Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol (2005) 1.15
The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease. Vasc Med (2012) 1.13
Exercise, body mass index, caloric intake, and cardiovascular mortality. Am J Prev Med (2003) 1.10
Variations in hip fracture hospitalization rates among different race/ethnicity groups in New York City. Ethn Dis (2004) 1.08
Differential use of coronary revascularization and hospital mortality following acute myocardial infarction. Arch Intern Med (2003) 1.05
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) (2011) 1.04
Impact of the increasing burden of diabetes on acute myocardial infarction in New York City: 1990-2000. Diabetes (2006) 1.02
Declining US stroke hospitalization since 1997: National Hospital Discharge Survey, 1988-2004. Neuroepidemiology (2008) 1.01
Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States. Am Heart J (2006) 1.00
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol (2004) 0.99
Clinical characteristics of stroke among Chinese in New York City. Ethn Dis (2004) 0.99
Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997. Am J Med (2002) 0.98
Sodium and cardiovascular disease. N Engl J Med (2014) 0.95
Is geography destiny for patients in New York with myocardial infarction? Am J Med (2003) 0.95
Sodium, blood pressure, and cardiovascular disease. Curr Opin Cardiol (2007) 0.94
Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology (2008) 0.93
Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens (2004) 0.92
The Cochrane review of sodium and health. Am J Hypertens (2011) 0.83
Exercise and cardiovascular outcomes by hypertensive status: NHANES I epidemiological follow-up study, 1971-1992. Am J Hypertens (2005) 0.82
Gender differences of revascularization in patients with acute myocardial infarction. Am J Cardiol (2006) 0.82
Quality of life in hypertensive patients: does it matter and should we measure it? J Hypertens (2005) 0.82
Stroke risk among Chinese immigrants in New York City. J Immigr Minor Health (2006) 0.81
Dietary Sodium and Cardiovascular Disease Risk. N Engl J Med (2016) 0.81
Blood-pressure-related disease is a global health priority. Am J Hypertens (2008) 0.80
Access to revascularization among patients with acute myocardial infarction in New York City--impact of hospital resources. J Urban Health (2006) 0.80
Podagra, uric acid, and cardiovascular disease. Circulation (2007) 0.79
Blood-pressure-related disease is a global health priority. J Hypertens (2008) 0.79
Resistant hypertension: a clinical syndrome in search of a definition. Am J Hypertens (2008) 0.78
Does blood pressure control require a Cuban-style revolution? J Hypertens (2006) 0.78
Hypertension control: improved, but not enough! Am J Hypertens (2007) 0.77
The return on INVEST. JAMA (2003) 0.76
ALLHAT and beyond. Am J Hypertens (2003) 0.75
Salt: data and speculation. Clin Auton Res (2002) 0.75
Does supplemental private insurance affect care of Medicare recipients hospitalized for myocardial infarction? Am J Public Health (2004) 0.75
Estimation of death rates from pandemic influenza. Lancet (2007) 0.75
Hypertension in sub-Saharan Africa: what physicians can do! Am J Hypertens (2009) 0.75
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT. J Clin Hypertens (Greenwich) (2013) 0.75
Blood pressure measures, relative and absolute risk, and international differences. J Hypertens (2002) 0.75
More about plasma renin and cardiovascular mortality. Eur Heart J (2011) 0.75
Dietary salt and cardiovascular disease. Lancet (2011) 0.75
Hypertension control and kidney disease: some questions answered, many remain. JAMA (2002) 0.75
AJH Peer Review 2014. Am J Hypertens (2015) 0.75
Clinical problems in the management of hypertension 1) Prehypertension: should we treat? 2)The very elderly: how should we treat. J Clin Hypertens (Greenwich) (2004) 0.75
Low sodium diet after DASH: has the situation changed? Dietary Approaches to Stop Hypertension. Curr Hypertens Rep (2002) 0.75
Randomized clinical trials: prescriptions to be applied with caution! Am J Hypertens (2008) 0.75
Editor's Note. The Renin-Angiotensin System: Today and Tomorrow in Research and Clinical Practice. Am J Hypertens (2011) 0.75
Revascularization among patients with acute myocardial infarction complicated by cardiogenic shock and impact of American College of Cardiology/American Heart Association guidelines. Am J Cardiol (2004) 0.75
AJH goes to China. Am J Hypertens (2008) 0.75
AJH, globalization, and the Chinese Journal of Hypertension. Am J Hypertens (2009) 0.75
Glucose-cholesterol interaction magnifies coronary heart disease risk for hypertensive patients. Hypertension (2004) 0.75
The state of the journal: a report to AJH readers, reviewers, and authors. Am J Hypertens (2011) 0.75
Renal dysfunction predicts attenuation of ischemic heart disease mortality risk from elevated glucose among treated hypertensive patients. Am J Hypertens (2006) 0.75
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? Stat Med (2012) 0.75